Research progress of B cells in pathogenesis and treatment of primary Sjögren's syndrome

GAO Yajing; WANG Hui; WANG Yongfu

doi:10.7619/jcmp.20211343

Journal of Clinical Medicine in Practice > 2021 > 25(14): 108-112. > DOI: 10.7619/jcmp.20211343

GAO Yajing, WANG Hui, WANG Yongfu. Research progress of B cells in pathogenesis and treatment of primary Sjögren's syndrome[J]. Journal of Clinical Medicine in Practice, 2021, 25(14): 108-112. DOI: 10.7619/jcmp.20211343

Citation:

PDF (599 KB)

Research progress of B cells in pathogenesis and treatment of primary Sjögren's syndrome

GAO Yajing¹,
WANG Hui¹,
WANG Yongfu^{1, 2, ,}

1.
Department of Rheumatology and Immunology, Institute of Rheumatology and Immunology of Baotou Medical College, First Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, 014010
2.
Key Laboratory of Autoimmunology in Inner Mongolia Autonomous Region, Baotou, Inner Mongolia, 014010

More Information

Received Date: March 26, 2021
Available Online: July 25, 2021
Published Date: July 27, 2021

Graphical Abstract

Abstract

Abstract

Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by dry eyes and dry mouth due to immune-mediated glandular involvement, patients with pSS may accompany by fatigue, skeletal muscle pain, and other systemic symptoms. B lymphocyte activation is a major feature of pSS, and elevated level of B-cell activating factor (BAFF) is associated with disease activity, ectopic germinal center formation, and serum autoantibody levels. Currently, the treatment methods for pSS are very limited, mainly focusing on improving dry symptoms, so it is necessary to gradually explore specific immunotherapy related to pSS. In this paper, the status quo of disease modifying antirheumatic drugs (DMARDs) regulating B cell therapy for PSS was reviewed and prospected.
- primary Sjögren's syndrome,
- B cell,
- B-cell activating factor,
- targeted therapy,
- antibody

FullText(HTML)

References (41)

References

[1]	MARIETTE X, CRISWELL L A. Primary Sjögren's syndrome[J]. N Engl J Med, 2018, 378(10): 931-939. doi: 10.1056/NEJMcp1702514
[2]	NOCTURNE G, MARIETTE X. Advances in understanding the pathogenesis of primary Sjögren's syndrome[J]. Nat Rev Rheumatol, 2013, 9(9): 544-556. doi: 10.1038/nrrheum.2013.110
[3]	RAMOS-CASALS M, BRITO-ZERÓN P, BOMBARDIERI S, et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies[J]. Ann Rheum Dis, 2020, 79(1): 3-18. doi: 10.1136/annrheumdis-2019-216114
[4]	CHRISTODOULOU M I, KAPSOGEORGOU E K, MOUTSOPOULOS H M. Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome[J]. J Autoimmun, 2010, 34(4): 400-407. doi: 10.1016/j.jaut.2009.10.004
[5]	PUGA I, COLS M, BARRA C M, et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen[J]. Nat Immunol, 2012, 13(2): 170-180. doi: 10.1038/ni.2194
[6]	BARCELOS F, MARTINS C, PAPOILA A, et al. Association between memory B-cells and clinical and immunological features of primary Sjögren's syndrome and Sicca patients[J]. Rheumatol Int, 2018, 38(6): 1063-1073. doi: 10.1007/s00296-018-4018-0
[7]	WANG R X, YU C R, DAMBUZA I M, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease[J]. Nat Med, 2014, 20(6): 633-641. doi: 10.1038/nm.3554
[8]	GREEN N M, MARSHAK-ROTHSTEIN A. Toll-like receptor driven B cell activation in the induction of systemic autoimmunity[J]. Semin Immunol, 2011, 23(2): 106-112. doi: 10.1016/j.smim.2011.01.016
[9]	LAVIE F, MICELI-RICHARD C, ITTAH M, et al. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome[J]. Scand J Immunol, 2008, 67(2): 185-192. doi: 10.1111/j.1365-3083.2007.02049.x
[10]	SCHNEIDER P, TSCHOPP J. BAFF and the regulation of B cell survival[J]. Immunol Lett, 2003, 88(1): 57-62. doi: 10.1016/S0165-2478(03)00050-6
[11]	KAMPA M, NOTAS G, STATHOPOULOS E N, et al. The TNFSF members APRIL and BAFF and their receptors TACI, BCMA, and BAFFR in oncology, with a special focus in breast cancer[J]. Front Oncol, 2020, 10: 827. doi: 10.3389/fonc.2020.00827
[12]	GROOM J, KALLED S L, CUTLER A H, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome[J]. J Clin Invest, 2002, 109(1): 59-68. doi: 10.1172/JCI0214121
[13]	MARIETTE X, ROUX S, ZHANG J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome[J]. Ann Rheum Dis, 2003, 62(2): 168-171. doi: 10.1136/ard.62.2.168
[14]	LAVIE F, MICELI-RICHARD C, QUILLARD J, et al. Expression of BAFF(BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome[J]. J Pathol, 2004, 202(4): 496-502. doi: 10.1002/path.1533
[15]	YOSHIMOTO K, SUZUKI K, TAKEI E, et al. Elevated expression of BAFF receptor, BR3, on monocytes correlates with B cell activation and clinical features of patients with primary Sjögren's syndrome[J]. Arthritis Res Ther, 2020, 22(1): 157. doi: 10.1186/s13075-020-02249-1
[16]	QUARTUCCIO L, SALVIN S, FABRIS M, et al. BLyS upregulation in Sjögren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands[J]. Rheumatology: Oxford, 2013, 52(2): 276-281. doi: 10.1093/rheumatology/kes180
[17]	DASS S, BOWMAN S J, VITAL E M, et al. Reduction of fatigue in Sjögren's syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study[J]. Ann Rheum Dis, 2008, 67(11): 1541-1544. doi: 10.1136/ard.2007.083865
[18]	MEIJER J M, MEINERS P M, VISSINK A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial[J]. Arthritis Rheum, 2010, 62(4): 960-968. doi: 10.1002/art.27314
[19]	CARUBBI F, CIPRIANI P, MARRELLI A, et al. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study[J]. Arthritis Res Ther, 2013, 15(5): R172. doi: 10.1186/ar4359
[20]	GOTTENBERG J E, CINQUETTI G, LARROCHE C, et al. Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry[J]. Ann Rheum Dis, 2013, 72(6): 1026-1031. doi: 10.1136/annrheumdis-2012-202293
[21]	HASEGAWA J, HAYAMI N, HOSHINO J, et al. Cryoglobulinemic vasculitis with primary Sjögren's syndrome: a case report[J]. Mod Rheumatol, 2018, 28(3): 570-574. doi: 10.3109/14397595.2015.1128870
[22]	DEVAUCHELLE-PENSEC V, MARIETTE X, JOUSSE-JOULIN S, et al. Treatment of primary Sjögren's syndrome with rituximab: a randomized trial[J]. Ann Intern Med, 2014, 160(4): 233-242. http://smartsearch.nstl.gov.cn/paper_detail.html?id=db9a3617d0fe2d931ca1a54e61f9b8d7
[23]	BOOTSMA H, KROESE F G M, VISSINK A. Editorial: rituximab in the treatment of Sjögren's syndrome: is it the right or wrong drug[J]. Arthritis Rheumatol, 2017, 69(7): 1346-1349. doi: 10.1002/art.40095
[24]	CORNEC D, COSTA S, DEVAUCHELLE-PENSEC V, et al. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome[J]. J Autoimmun, 2016, 67: 102-110. doi: 10.1016/j.jaut.2015.11.002
[25]	MARIETTE X, SEROR R, QUARTUCCIO L, et al. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase Ⅱ study[J]. Ann Rheum Dis, 2015, 74(3): 526-531. doi: 10.1136/annrheumdis-2013-203991
[26]	QUARTUCCIO L, SALVIN S, CORAZZA L, et al. Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase Ⅱ open-label BELISS study[J]. Clin Exp Rheumatol, 2016, 34(2): 311-314. http://smartsearch.nstl.gov.cn/paper_detail.html?id=abf10f5df1c3a2fde8589c36ac82b96f
[27]	DÖRNER T, POSCH M G, LI Y, et al. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity[J]. Ann Rheum Dis, 2019, 78(5): 641-647. doi: 10.1136/annrheumdis-2018-214720
[28]	SIEGER N, FLEISCHER S J, MEI H E, et al. CD22 ligation inhibits downstream B cell receptor signaling and Ca²⁺ flux upon activation[J]. Arthritis Rheum, 2013, 65(3): 770-779. doi: 10.1002/art.37818
[29]	STEINFELD S D, TANT L, BURMESTER G R, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase Ⅰ/Ⅱ study[J]. Arthritis Res Ther, 2006, 8(4): R129. doi: 10.1186/ar2018
[30]	GOTTENBERG J E, DÖRNER T, BOOTSMA H, et al. Efficacy of epratuzumab, an anti-CD22 monoclonal IgG antibody, in systemic lupus erythematosus patients with associated Sjögren's syndrome: post hoc analyses from the EMBODY trials[J]. Arthritis Rheumatol, 2018, 70(5): 763-773. doi: 10.1002/art.40425
[31]	ALEVIZOS I, ZHENG C, COTRIM A P, et al. Late responses to adenoviral-mediated transfer of the aquaporin-1 gene for radiation-induced salivary hypofunction[J]. Gene Ther, 2017, 24(3): 176-186. doi: 10.1038/gt.2016.87
[32]	LAI Z, YIN H, CABRERA-PÉREZ J, et al. Aquaporin gene therapy corrects Sjögren's syndrome phenotype in mice[J]. PNAS, 2016, 113(20): 5694-5699. doi: 10.1073/pnas.1601992113
[33]	YIN H, CABRERA-PEREZ J, LAI Z, et al. Association of bone morphogenetic protein 6 with exocrine gland dysfunction in patients with Sjögren's syndrome and in mice[J]. Arthritis Rheum, 2013, 65(12): 3228-3238. http://www.ncbi.nlm.nih.gov/pubmed/23982860
[34]	XU J, SU Y, HU L, et al. Effect of bone morphogenetic protein 6 on immunomodulatory functions of salivary gland-derived mesenchymal stem cells in Sjögren's syndrome[J]. Stem Cells Dev, 2018, 27(22): 1540-1548. doi: 10.1089/scd.2017.0161
[35]	YIN H, KALRA L, LAI Z, et al. Inhibition of bone morphogenetic protein 6 receptors ameliorates Sjögren's syndrome in mice[J]. Sci Rep, 2020, 10(1): 2967. doi: 10.1038/s41598-020-59443-z
[36]	CORNETH O B J, VERSTAPPEN G M P, PAULISSEN S M J, et al. Enhanced bruton's tyrosine kinase activity in peripheral blood B lymphocytes from patients with autoimmune disease[J]. Arthritis Rheumatol, 2017, 69(6): 1313-1324. doi: 10.1002/art.40059
[37]	MUNAKATA W, ANDO K, HATAKE K, et al. Phase Ⅰ study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan[J]. Cancer Sci, 2019, 110(5): 1686-1694. doi: 10.1111/cas.13983
[38]	NAYAR S, CAMPOS J, SMITH C G, et al. Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome[J]. Ann Rheum Dis, 2019, 78(2): 249-260. http://ard.bmj.com/content/78/2/249.full
[39]	ZENG M, SZYMCZAK M, AHUJA M, et al. Restoration of CFTR activity in ducts rescues acinar cell function and reduces inflammation in pancreatic and salivary glands of mice[J]. Gastroenterology, 2017, 153(4): 1148-1159. http://www.ncbi.nlm.nih.gov/pubmed/28634110/
[40]	SINTES J, VIDAL-LALIENA M, ROMERO X, et al. Characterization of mouse CD229(Ly9), a leukocyte cell surface molecule of the CD150(SLAM) family[J]. Tissue Antigens, 2007, 70(5): 355-362. doi: 10.1111/j.1399-0039.2007.00909.x
[41]	BRALEY-MULLEN H, YU S. NOD. H-2h4 mice: an important and underutilized animal model of autoimmune thyroiditis and Sjögren's syndrome[J]. Adv Immunol, 2015, 126: 1-43.

[1]	GU Xin, JING Liwei, WANG Andi, LIU Jun, DAI Yongqiang, ZHANG Baoling. Analysis of the recurrence rate and risk factors of renal calculi after intracavitary lithotripsy[J]. Journal of Clinical Medicine in Practice, 2024, 28(10): 39-41. DOI: 10.7619/jcmp.20232864
[2]	YANG Xingfei, LI Shanshan, LI Zhuo. Effects of single-port laparoscopic extraperitoneal ligation on surgical indexes, intestinal mucosal barrier function and recurrence rate in children with pediatric inguinal hernia[J]. Journal of Clinical Medicine in Practice, 2024, 28(7): 75-78. DOI: 10.7619/jcmp.20234152
[3]	LIU Xiaohong, LI Mei, WANG Fengyun, SI Yuchen, DU Xiaoli, SHI Liangliang, SHAO Haiou, CHEN Li, ZHANG Hongyan. Effect of modified Qiankun Yudan Decoction combined with leuprorelin acetate on serum carbohydrate antigen 125 and recurrence rate in patients with adenomyosis[J]. Journal of Clinical Medicine in Practice, 2023, 27(18): 133-137. DOI: 10.7619/jcmp.20231988
[4]	WANG Buyun, LEI Lei. Effect of tension-free herniorrhaphy in treating inguinal hernia in the elderly patients[J]. Journal of Clinical Medicine in Practice, 2020, 24(8): 104-106. DOI: 10.7619/jcmp.202008028
[5]	LIU Yi, WANG Guanglei. Effect of Beifuji combined with Rehabilitation Fluid on recurrent oral ulcer and its influence on inflammatory factors and recurrence rate[J]. Journal of Clinical Medicine in Practice, 2019, (4): 90-92,95. DOI: 10.7619/jcmp.201904027
[6]	CHEN Xiaohong, HUANG Xia. Effect of comprehensive nursing intervention on the compliance behavior and recurrence rate of patients with lumbar disc herniation[J]. Journal of Clinical Medicine in Practice, 2017, (12): 70-72. DOI: 10.7619/jcmp.201712021
[7]	LI Shuiyan, LUO Dejun. Effect of reason-targeted nursing on health behavior and recurrence rate of patients with peptic ulcer[J]. Journal of Clinical Medicine in Practice, 2016, (8): 50-52. DOI: 10.7619/jcmp.201608016
[8]	DONG Shuling, DONG Lingzhi, REN Zhiyan. Influence of nursing intervention on reduction of incidence rate of complications in hypertension patients[J]. Journal of Clinical Medicine in Practice, 2013, (20): 18-20. DOI: 10.7619/jcmp.201320006
[9]	XU Zhuowen, ZHENG Ruolong, LI Weizhang, CHEN Jianbo, QIAN Huidong, CHEN Xinjun. Impact of obstructive sleep apnea syndrome on the recurrent rate of patients with atrial fibrillation after radiofrequency ablation[J]. Journal of Clinical Medicine in Practice, 2013, (9): 23-25. DOI: 10.7619/jcmp.201309007
[10]	YANG Yan. Influence of comprehensive nursing intervention on compliance of medication and recurrence rate in discharged patients with schizophrenia[J]. Journal of Clinical Medicine in Practice, 2013, (8): 55-57. DOI: 10.7619/jcmp.201308021

Cited By

Cited by

Periodical cited type(5)

1.	王燕，汪晶晶，王红丽，孔羽. 急性脑梗死并认知功能障碍的血清生化指标预测研究. 黑龙江医学. 2025(06): 659-662 .
2.	栗昭生，那丽莎，关亚新，张忠敏. 孤立性丘脑梗死后发生认知障碍的影响因素分析. 中国当代医药. 2024(14): 29-32 .
3.	叶双双，齐智慧. 灯盏生脉胶囊对脑梗死认知障碍的影响. 光明中医. 2024(13): 2626-2629 .
4.	燕炼钢，周婷，贾泽坤，杨娅，江娜，何彦蓉，王储蓄，殷红彪. 针刺阳明经配合补阳还五汤加减治疗气虚血瘀型脑梗死的效果分析. 实用临床医药杂志. 2023(22): 105-109 . 本站查看
5.	齐赛卿，张亚伟，李君朝，申志国. 丹参多酚酸盐联合依达拉奉对急性脑梗死患者认知、脑动脉搏动指数及血清视锥蛋白样蛋白-1水平的影响. 实用临床医药杂志. 2023(22): 114-117+122 . 本站查看

Other cited types(1)

Get Citation

PDF

XML

Article views (480) PDF downloads (63) Cited by(6)

Turn off MathJax

Article Contents

Abstract

References

Research progress of B cells in pathogenesis and treatment of primary Sjögren's syndrome

Abstract

References

Related Articles

Cited by

Periodical cited type(5)

Other cited types(1)

Catalog

Research progress of B cells in pathogenesis and treatment of primary Sjögren's syndrome

Abstract

References

Related Articles

Cited by

Periodical cited type(5)

Other cited types(1)

Catalog

Export File

Citation

Format

Content